Concord Drugs Reports 31% Revenue Growth and Quadrupled Profit in Q1
Concord Drugs Limited reported robust Q1 financial results. Consolidated revenue reached Rs 1,360.64 crore, up 31% quarter-on-quarter and 16.4% year-on-year. Net profit surged to Rs 11.77 crore, a threefold increase from the previous quarter and more than fourfold from the same period last year. Standalone revenue was Rs 1,338.35 crore with Rs 11.14 crore net profit. The company's subsidiary, Proton Remedies Private Limited, contributed Rs 40.44 crore to revenue and Rs 0.62 crore to profit. Basic EPS improved to Rs 0.12, and the company reported no loan defaults.
30Jun 25
Concord Drugs to Hold Board Meeting on Fundraising Initiatives
Concord Drugs Ltd has announced a board meeting on July 3 to discuss fundraising and capital raising initiatives. The meeting signals the company's active consideration of strategies to strengthen its financial position, which could potentially support various aspects of operations such as research and development, facility expansion, market growth, debt reduction, or working capital requirements.